ライフサイエンスコーパス: coronary heart disease

1 ardial infarction, ischemic stroke, or fatal coronary heart disease).

2 risk (acute myocardial infarction and fatal coronary heart disease).

3 ry artery disease events, and mortality from coronary heart disease.

4 rom air pollution is associated with risk of coronary heart disease.

5 D), arterial hypertension, dyslipidemia, and coronary heart disease.

6 ineered vascular grafts (TEVGs) for treating coronary heart disease.

7 for heart failure, and 4.33 (3.82-4.91) for coronary heart disease.

8 led to reduced morbidity and mortality from coronary heart disease.

9 as associated with myocardial infarction and coronary heart disease.

10 a platform for assessing central aspects of coronary heart disease.

11 pathophysiological mechanism in migraine and coronary heart disease.

12 not be extrapolated to patients with stable coronary heart disease.

13 are independent and causal risk factors for coronary heart disease.

14 iovascular disease, and those with prevalent coronary heart disease.

15 ical functioning, diabetes, hypertension, or coronary heart disease.

16 JAK2 were each individually associated with coronary heart disease.

17 ation, or both were causally associated with coronary heart disease.

18 le lipid profiles, have reduced incidence of coronary heart disease.

19 s involving 10 195 patients with established coronary heart disease.

20 3, and had a previous history of MI, IS, or coronary heart disease.

21 lipoprotein(a) pathway is a causal factor in coronary heart disease.

22 circulating lipoprotein(a) concentration, to coronary heart disease.

23 own to play a key role in the development of Coronary Heart Disease.

24 prevention populations are mostly limited to coronary heart disease.

25 ke or transient ischemic attack and no known coronary heart disease.

26 ndary prevention treatment for patients with coronary heart disease.

27 ins that may serve as risk factors for human coronary heart diseases.

28 ascular disease, 0.30 (CI, 0.19 to 0.48) for coronary heart disease, 0.41 (CI, 0.32 to 0.52) for infe

29 io [OR] 1.32 [95% CI 1.17-1.48]) and to have coronary heart disease (1.33 [1.14-1.54]), chronic lung

30 th (OR 1.32 [95% CI 1.10-1.58]) and incident coronary heart disease (1.66 [1.18-2.35]), stroke (1.48

31 5% confidence interval (CI): 1.04, 1.22) for coronary heart disease, 1.20 (95% CI: 1.01, 1.42) for he

32 e, -26.0 (95% CI, -42.6 to -9.4); death from coronary heart disease, -21.7 (95% CI, -37.1 to -6.4); a

33 including 506100 from heart disease (371266 coronary heart disease, 35019 hypertensive heart disease

34 ted with both haematological cancer(2-4) and coronary heart disease(5)-this phenomenon is termed clon

35 ular mortality, noncardiovascular mortality, coronary heart disease, acute myocardial infarction, str

36 2 diabetes, inflammatory bowel disease, and coronary heart disease, all of which have available earl

37 ariants at the CXCR4 locus with the risk for coronary heart disease, along with CXCR4 transcript expr

38 he epidemics of type 2 diabetes mellitus and coronary heart disease already faced by South Asian coun

39 Air pollution exposure has been linked to coronary heart disease, although evidence on PM2.5 and m

40 ibutor to disproportionately higher rates of coronary heart disease among American Indians and Alaska

41 hazard ratios for cardiovascular disease and coronary heart disease among participants who consumed 1

42 was associated with a lower risk of incident coronary heart disease among participants with the Hp2-2

43 ign and genetic data on 60 801 patients with coronary heart disease and 123 504 controls from the CAR

44 e 911 CVD events (including 609 incidents of coronary heart disease and 270 strokes).

45 hat together enrolled 4726 participants with coronary heart disease and 3529 controls.

46 ent after menopause, of whom 9369 (3.1%) had coronary heart disease and 4338 (1.4%) had strokes.

47 Coronary heart disease and asthma or chronic obstructive

48 derly individuals at low short-term risk for coronary heart disease and cardiovascular disease.

49 recognized as an independent risk factor for coronary heart disease and cardiovascular mortality.

50 ASCV mortality, defined as death because of coronary heart disease and cerebrovascular or other athe

51 therapy was effective at preventing incident coronary heart disease and CVD events in ACCORD study pa

52 n for the management of patients with stable coronary heart disease and discuss implications for the

53 by medications for various diseases (such as coronary heart disease and heart attack) and many beta-a

54 In UK Biobank, a combination of coronary heart disease and heart failure in addition to

55 with numerous cardiac conditions, including coronary heart disease and heart failure-the 2 most comm

56 on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance is

57 Chinese patients with coronary heart disease and impaired glucose tolerance we

58 INTERPRETATION: In Chinese patients with coronary heart disease and impaired glucose tolerance, a

59 Incidence of coronary heart disease and invasive breast cancer (the t

60 Individuals with CHIP have a doubled risk of coronary heart disease and ischemic stroke, and worsened

61 The effect of pravastatin versus placebo on coronary heart disease and major adverse cardiovascular

62 ar events in ambulatory patients with stable coronary heart disease and may merit routine use.

63 ia, and associated with an increased risk of coronary heart disease and myocardial infarction.

64 and 67% (HR: 0.33; 95% CI: 0.19 to 0.57) for coronary heart disease and stroke combined (p for trend

65 978, a sharp decline in mortality rates from coronary heart disease and stroke has become unmistakabl

66 century, then the decline in mortality from coronary heart disease and stroke has been the success s

67 cluded that a significant recent downtick in coronary heart disease and stroke mortality rates had de

68 randomization estimates for drug effects on coronary heart disease and stroke risk were compared wit

69 randomization estimates for their effect on coronary heart disease and stroke risk, respectively, we

70 ss DM trial arms, especially with respect to coronary heart disease and stroke subtypes.

71 f PCSK9 LOF variants with LDL-C and incident coronary heart disease and stroke through a meta-analysi

72 Outcomes included cumulative CVD (coronary heart disease and stroke) deaths prevented or p

73 and cardiovascular disease status (including coronary heart disease and stroke) were included.

74 3, 1.56); SBP was positively associated with coronary heart disease and stroke.

75 l therapy alone in patients with established coronary heart disease and type 2 diabetes (T2DM).

76 ex and is associated with polygenic risk for coronary heart disease and type 2 diabetes.

77 herosclerosis is the major cause of ischemic coronary heart diseases and characterized by the infiltr

78 reported was 32 [13%] of 247 individuals for coronary heart disease), and respiratory conditions (eg,

79 ad suffered from CVD, 4.9% had suffered from coronary heart disease, and 2.6% had experienced a strok

80 rs, cardiovascular risk factors, presence of coronary heart disease, and electrocardiographic paramet

81 lthier lifestyles and fewer risk factors for coronary heart disease, and particularly those with favo

82 ic types of nuts and cardiovascular disease, coronary heart disease, and stroke risk.

83 ity (ie, at least two from: type 2 diabetes, coronary heart disease, and stroke) in adults who are ov

84 iseases (heart failure, atrial fibrillation, coronary heart disease, and stroke) with subsequent risk

85 veloping at least two from: type 2 diabetes, coronary heart disease, and stroke).

86 dent myocardial infarction or death owing to coronary heart disease, and stroke, defined as the first

87 ve hypertension, chronic kidney disease, HF, coronary heart disease, and stroke.

88 -related metrics like time-to-death, time-to-coronary heart disease, and time-to-cancer.

89 Prevalence of hypertension, coronary heart disease, and type 2 diabetes were determi

90 recommendations for patients with prevalent coronary heart disease, and we offer recommendations, wh

91 the incidence and morbidity of hypertension, coronary heart disease, arrhythmia, heart failure, and s

92 n numerous pathological processes, including coronary heart disease, arterial and venous thrombosis,

93 ducible myocardial ischemia to understanding coronary heart disease as multifactorial, chronic diseas

94 an-diagnosed myocardial infarction, or fatal coronary heart disease) ascertained during the study per

95 cessfully reproduces prior knowledge of diet-coronary heart disease associations in the epidemiologic

96 with low-density lipoprotein cholesterol and coronary heart disease at APOB were cis-methylation quan

97 eclassification improvements for early-onset coronary heart disease, atrial fibrillation and prostate

98 idence interval, 8.38 to 15.50), followed by coronary heart disease, atrial fibrillation, and stroke.

99 Antidiastole of coronary heart disease, atrial septal defect, and atrial

100 inogen, is associated with increased risk of coronary heart disease, but its relevance for stroke typ

101 rche has been associated with higher risk of coronary heart disease, but the mechanisms underlying th

102 lar disease, pravastatin reduced the risk of coronary heart disease by 27% (P=0.002) and major advers

103 /=190 mg/dL, pravastatin reduced the risk of coronary heart disease by 27% (P=0.033) and major advers

104 Adverse events from coronary heart disease can be mitigated or avoided with

105 rs), 1203 incident CVD events, including 916 coronary heart disease cases, were reported.

106 althy obese individuals had a higher risk of coronary heart disease, cerebrovascular disease, and hea

107 nary artery calcium (CAC) is associated with coronary heart disease (CHD) and cardiovascular disease

108 While comorbidity between coronary heart disease (CHD) and depression is evident,

109 The association of coronary heart disease (CHD) and human immunodeficiency

110 infection is an independent risk factor for coronary heart disease (CHD) and is associated with pert

111 ally instrumented blood sucrose with risk of coronary heart disease (CHD) and its risk factors (i.e.,

112 cancer were the primary trial outcomes, and coronary heart disease (CHD) and overall CVD were additi

113 stasis and, therefore, in the development of coronary heart disease (CHD) and periodontitis.

114 are predominantly based on investigations of coronary heart disease (CHD) and stroke, although smokin

115 ascular disease (ASCVD) events, inclusive of coronary heart disease (CHD) and stroke, and is a decisi

116 s of cardiovascular disease (CVD), including coronary heart disease (CHD) and stroke, and type 2 diab

117 usly been associated with lower incidence of coronary heart disease (CHD) and type 2 diabetes (T2D) b

118 entified several metabolites associated with coronary heart disease (CHD) and type 2 diabetes.

119 Because polygenic risk scores (PRSs) for coronary heart disease (CHD) are derived from mainly Eur

120 otein(a) (Lp[a]) and family history (FHx) of coronary heart disease (CHD) are individually associated

121 d 15,837 incident CVD cases, including 9,794 coronary heart disease (CHD) cases and 6,174 strokes.

122 in 14 prospective studies supplemented with coronary heart disease (CHD) data from CARDIoGRAMplusC4D

123 Results A total of 290 participants had hard coronary heart disease (CHD) events (207 myocardial infa

124 rmine the long-term risks of acute and fatal coronary heart disease (CHD) events after sepsis hospita

125 s, is a significant independent predictor of coronary heart disease (CHD) events and mortality.

126 These patients may be at increased risk for coronary heart disease (CHD) events and mortality.

127 Rates for recurrent coronary heart disease (CHD) events have declined in the

128 H) are individually associated with incident coronary heart disease (CHD) events.

129 with family history of diabetes, asthma, and coronary heart disease (CHD) in 42,940 adults spanning 8

130 improve understanding of the epidemiology of coronary heart disease (CHD) in the USA.

131 ariant (rs10911021) has been associated with coronary heart disease (CHD) in type 2 diabetes.

132 sociations of long-term changes in TMAO with coronary heart disease (CHD) incidence.

133 Blacks have higher coronary heart disease (CHD) mortality compared with whi

134 count appears to predict total mortality and coronary heart disease (CHD) mortality, but it is unclea

135 ns among patients with PAD versus those with coronary heart disease (CHD) or cerebrovascular disease.

136 zed, single-blind, controlled trial in 1,002 coronary heart disease (CHD) patients, whose primary obj

137 It is unclear how coronary heart disease (CHD) risk across the adult life

138 ith increased myocardial infarction (MI) and coronary heart disease (CHD) risks (MI odds ratio (OR) =

139 s (SNPs) could be useful for population-wide coronary heart disease (CHD) screening.

140 en have lower age-specific rates of incident coronary heart disease (CHD) than men.

141 Whether disclosing genetic risk for coronary heart disease (CHD) to individuals influences i

142 , they also proposed an alternative: whether coronary heart disease (CHD) was preventable at all by s

143 tive associations of LDL-C with IS than with coronary heart disease (CHD)(6,7), but LDL-C-lowering tr

144 telomere length (TL) to be a risk factor for coronary heart disease (CHD), and recently the associati

145 differences of incident heart failure (HF), coronary heart disease (CHD), and stroke in participants

146 e associations of PCOS with type 2 diabetes, coronary heart disease (CHD), and stroke.

147 botic events, such as those with established coronary heart disease (CHD), are lacking.

148 DNA methylation is implicated in coronary heart disease (CHD), but current evidence is ba

149 Periodontal disease has been linked to coronary heart disease (CHD), but studies have been inco

150 P-T2D interactions at 13 variants, including coronary heart disease (CHD), CKD, PAD and neuropathy.

151 ascular disease (CVD) mortality and incident coronary heart disease (CHD), CVD, and cancer over a mea

152 calculated and linked to subsequent risks of coronary heart disease (CHD), heart failure (HF), or str

153 learance pathway that are protective against coronary heart disease (CHD), independently of LDL chole

154 To optimize preventive strategies for coronary heart disease (CHD), it is essential to underst

155 ary outcomes were incident fatal or nonfatal coronary heart disease (CHD), stroke, and CVD (composite

156 tate (CEE+MPA) resulted in increased risk of coronary heart disease (CHD), whereas oral conjugated eq

157 Odds ratio (OR) for coronary heart disease (CHD)-defined as coronary death,

158 ty in patients with suspected or established coronary heart disease (CHD).

159 scaled to 10% reduction in relative risk of coronary heart disease (CHD).

160 omosome 9p21 is a recognized risk factor for coronary heart disease (CHD).

161 r prognostic factors, including pre-existing coronary heart disease (CHD).

162 rdiovascular disease (CVD) and in particular coronary heart disease (CHD).

163 accepted model to predict outcomes in stable coronary heart disease (CHD).

164 HDL defined by apoC-III are associated with coronary heart disease (CHD).

165 has been associated with type 2 diabetes and coronary heart disease (CHD).

166 consumption to blood lipid levels and hence coronary heart disease (CHD).

167 , 58.5 years; 39% women) with 62240 cases of coronary heart disease (CHD).

168 ailed to demonstrate a reduction in risk for coronary heart disease (CHD).

169 Diabetes mellitus is a major risk factor for coronary heart disease (CHD).

170 Circulating lipoprotein lipids cause coronary heart disease (CHD).

171 ulin; reduces HDLs; and may increase risk of coronary heart disease (CHD).

172 r the known interaction of periodontitis and coronary heart disease (CHD).

173 for the C variant have an increased risk for coronary heart disease (CHD).

174 diseases (CVDs; 0.25%; 95% PI: 0.13, 0.37), coronary heart disease (CHD; 0.21%; 95% PI: 0.05, 0.36),

175 ine associations between hs-TnI and incident coronary heart disease (CHD; myocardial infarction and f

176 influence of a modern lifestyle in abetting Coronary Heart Diseases (CHD) have mostly focused on det

177 cord of 1 of 4 cardiovascular presentations (coronary heart disease [CHD], cerebrovascular disease, h

178 ntration with first-ever CVD outcomes (i.e., coronary heart disease [CHD], stroke, or the combination

179 We studied the future risk of heart failure, coronary heart disease, composite cardiovascular disease

180 from the GENIUS-CHD (Genetics of Subsequent Coronary Heart Disease) Consortium (73.1% male, mean age

181 from the GENIUS-CHD (Genetics of Subsequent Coronary Heart Disease) consortium involving patients wi

182 ts who were not diagnosed with angina due to coronary heart disease, coronary CTA was associated with

183 ling was used to determine hazard ratios for coronary heart disease, CVD, and all-cause mortality acc

184 n a sex-stratified analysis, the increase in coronary heart disease, CVD, and all-cause mortality in

185 BMI, obese individuals had a higher risk of coronary heart disease, CVD, and all-cause mortality whi

186 ted with a higher risk of CAC and subsequent coronary heart disease, CVD, and all-cause mortality.

187 ghest event rate, with a 10-fold increase in coronary heart disease death or nonfatal myocardial infa

188 Coronary heart disease death or nonfatal myocardial infa

189 ed plaque burden confer an increased risk of coronary heart disease death or nonfatal myocardial infa

190 ring the initial trial phase and the risk of coronary heart disease death, cardiovascular death, and

191 Evolocumab reduced the risk of coronary heart disease death, myocardial infarction, or

192 in the highest quartile had a higher risk of coronary heart disease death, myocardial infarction, or

193 ccurrence of the primary composite end point-coronary heart disease death, nonfatal myocardial infarc

194 me (major adverse cardiovascular events, ie, coronary heart disease death, nonfatal myocardial infarc

195 primary MACEs endpoint was the composite of coronary heart disease death, nonfatal myocardial infarc

196 The primary MACE outcome was coronary heart disease death, nonfatal myocardial infarc

197 verse cardiovascular events (MACE) comprised coronary heart disease death, nonfatal myocardial infarc

198 Incident CVD, which combines coronary heart disease, defined as the first incident my

199 South Asian populations including premature coronary heart disease, early type 2 diabetes mellitus,

200 g a common source epidemic, such as diet and coronary heart disease, especially in populations with r

201 g a common-source epidemic, such as diet and coronary heart disease, especially in populations with r

202 disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke.

203 d nongenetic effects on the indexing (first) coronary heart disease event.

204 nefit from statin therapy to prevent a first coronary heart disease event.

205 hospitalization, or death from CVD; n=431), coronary heart disease events (MI or death from coronary

206 ed sugars, is associated with a reduction in coronary heart disease events and death.

207 enic risk score was associated with incident coronary heart disease events but did not significantly

208 cular mass was strongly associated with hard coronary heart disease events, other cardiovascular deat

209 st cancer, fractures, thromboembolic events, coronary heart disease events, stroke, endometrial cance

210 ity or cardiorespiratory fitness and reduced coronary heart disease events.

211 The Genetics of Subsequent Coronary Heart Disease (GENIUS-CHD) consortium was estab

212 ation between Bisphenol A (BPA) exposure and coronary heart disease has been shown, but not in patien

213 .46; 95% confidence interval, 1.14-1.87) and coronary heart disease (hazard ratio, 1.56; 95% confiden

214 k for certain cardiovascular diseases (e.g., coronary heart disease, heart failure, and atrial fibril

215 applications to 3 cardiovascular endpoints (coronary heart disease, heart failure, and atrial fibril

216 l cardiovascular disease and its components (coronary heart disease, heart failure, and stroke) were

217 ed visit 5 (2011-2013) and were free of CVD (coronary heart disease, heart failure, or stroke).

218 azard ratios for persons with prevalent CVD (coronary heart disease, heart failure, or stroke).

219 stimated for patients with new-onset stroke, coronary heart disease, heart failure, peripheral arteri

220 stimated for patients with new-onset stroke, coronary heart disease, heart failure, peripheral arteri

221 ncreases in the incidence and progression of coronary heart disease, heart failure, stroke, and atria

222 ythm disorders, subclinical atherosclerosis, coronary heart disease, heart failure, valvular disease,

223 .99 to 1.32), but higher risks of death from coronary heart disease (HR: 1.45; 95% CI: 1.21 to 1.74),

224 markers with mean DLRs of 0.20 and 0.20 for coronary heart disease (i.e., ~80% lower risk than expec

225 ECG) parameters in individuals free of prior coronary heart disease in four different ethnicities.

226 ciated with nearly a doubling in the risk of coronary heart disease in humans and with accelerated at

227 ned data from 3313 patients with established coronary heart disease in the Ludwigshafen Risk and Card

228 s of cardiovascular disease, with a focus on coronary heart disease, in the setting of HIV infection,

229 tic locus is associated with CVD, especially coronary heart disease, in the setting of hyperglycemia.

230 cidence, 0.80 (0.67-0.96; P trend=0.005) for coronary heart disease incidence, 0.66 (0.52-0.84; P tre

231 was associated with lower risk of total CVD, coronary heart disease incidence, and mortality because

232 , defined as a composite outcome of incident coronary heart disease (including heart attack and angin

233 Coronary heart disease is a chronic, systemic disease wi

234 easure to predict progression to death after coronary heart disease is established.

235 clinically meaningful reductions in rates of coronary heart disease, ischemic stroke, and total cardi

236 All analyses were repeated for incident coronary heart disease (MI or CVD death) and association

237 rbanization level, hyperlipidemia, diabetes, coronary heart disease, migraine, hypotension, and obstr

238 confidence intervals (CIs) for all-cause and coronary heart disease mortality, myocardial infarction,

239 al and nonfatal myocardial infarction, other coronary heart disease mortality, or stroke; (3) ASCV mo

240 lar risk of incident cardiovascular disease (coronary heart disease, myocardial infarction, stroke an

241 The risk of coronary heart disease, myocardial infarction, stroke an

242 ailure, n=1269; atrial fibrillation, n=1337; coronary heart disease, n=696; and stroke, n=559) and 21

243 onary heart disease events (MI or death from coronary heart disease; (n=277), stroke (n=68), HF event

244 imary endpoint was a composite of death from coronary heart disease, non-fatal myocardial infarction,

245 4; P=5.6*10(-5)) and a 3-fold higher risk of coronary heart disease (odds ratio, 3.03; 95% CI, 1.29-7

246 were associated with a pooled odds ratio for coronary heart disease of 0.51 (95% CI, 0.28-0.92) in bl

247 15-29 ml/min per 1.73 m(2)), heart disease (coronary heart disease or heart failure), and stroke, an

248 food frequency questionnaire and no baseline coronary heart disease or HF.

249 ography (CTA) reduced the rate of death from coronary heart disease or nonfatal myocardial infarction

250 espectively 1,987 deaths and 680 adjudicated coronary heart disease or stroke events had occurred.

251 ion Trial to show a significant reduction in coronary heart disease or total mortality to the design

252 ion Trial to show a significant reduction in coronary heart disease or total mortality to the design

253 A1369S was associated with a reduced risk of coronary heart disease (OR 0.98; 95% CI 0.96, 0.99; P =

254 s for fatal and nonfatal CVD events (stroke, coronary heart disease, or heart failure) were estimated

255 troke, nonfatal myocardial infarction, fatal coronary heart disease, or heart failure.

256 d participants with a diagnosis of diabetes, coronary heart disease, or stroke at or before study bas

257 03; 71 445 women) who did not have diabetes, coronary heart disease, or stroke at study baseline (197

258 Coronary CTA improves coronary heart disease outcomes by enabling better targe

259 incident cardiovascular disease (P < 0.001), coronary heart disease (P = 0.015), and heart failure (P

260 PHDL-C=0.008 and Ptriglycerides=0.00003) and coronary heart disease (P=0.0007).

261 ignaling is associated with reduced risks of coronary heart disease, peripheral arterial disease, and

262 ed genetic links are also seen with obesity, coronary heart disease, psychiatric diseases, cognitive

263 -term mortality in patients with established coronary heart disease remains less clear.

264 ociation of 257 nutrients and 117 foods with coronary heart disease risk (acute myocardial infarction

265 the effect of the genetic score on decreased coronary heart disease risk extended beyond its effect o

266 esting a shared mechanism linking lipids and coronary heart disease risk mediated via platelet aggreg

267 decreased triglyceride levels, and decreased coronary heart disease risk that have the same direction

268 is had an 11% lower risk of CVD, a 15% lower coronary heart disease risk, a 25% lower CVD mortality,

269 mellitus and prediabetes remain at increased coronary heart disease risk.

270 ansition (MT) contributes to the increase in coronary heart disease risk.

271 the associations of specific nutrients with coronary heart disease risk.

272 ed by the ABC-CHD (Age, Biomarkers, Clinical-Coronary Heart Disease) risk score (p for interaction =

273 infarction (RR, 0.92 [CI, 0.85 to 0.99]) and coronary heart disease (RR, 0.93 [CI, 0.89 to 0.98]).

274 isease after menopause and typically develop coronary heart disease several years later than men.

275 causal association of obesity with diabetes, coronary heart disease, specific cancers, and other cond

276 The hazard ratios for incident coronary heart disease, stroke, and CVD associated with

277 repeat measures of cardiometabolic disease (coronary heart disease, stroke, and type 2 diabetes) fro

278 of multimorbidity (two or more of diabetes, coronary heart disease, stroke, chronic obstructive pulm

279 hite adults in cardiovascular disease (CVD), coronary heart disease, stroke, heart failure (HF), and

280 ncident CVD (composite of fatal and nonfatal coronary heart disease, stroke, heart failure, and other

281 Composite CVD events, including coronary heart disease, stroke, heart failure, and other

282 utcome and Measures: Incident CVD, including coronary heart disease, stroke, or death from cardiovasc

283 The outcome was a composite of nonfatal coronary heart disease, stroke, transient ischemic attac

284 obesity on her offspring's risks of obesity, coronary heart disease, stroke, type 2 diabetes, and ast

285 pathophysiological mechanism in migraine and coronary heart disease such as endothelial dysfunction o

286 y lipoprotein cholesterol, and lower risk of coronary heart disease suggested that pharmacological in

287 tive cohorts, carriers of CHIP had a risk of coronary heart disease that was 1.9 times as great as in

288 here is no effect modification by history of coronary heart disease, the false-positive rates of asso

289 al risk factors to test genome-wide PRSs for coronary heart disease, type 2 diabetes, atrial fibrilla

290 Conclusion In older adults without prior coronary heart disease, underlying greater LV diffuse fi

291 lood cells and associated such presence with coronary heart disease using samples from four case-cont

292 Coronary heart disease was an independent predictor of m

293 Increased severity of coronary heart disease was associated with lipoprotein(a

294 , they also proposed an alternative: whether coronary heart disease was preventable at all by simulta

295 y of APOC3 has been shown to protect against coronary heart disease; we identified APOC3 homozygous p

296 ex, black race, body mass index, or baseline coronary heart disease were detected.

297 hat the CETP inhibitor anacetrapib decreased coronary heart disease when added to statin therapy.

298 Despite the reduced incidence of coronary heart disease with intensive risk factor manage

299 In patients with coronary heart disease with T2DM, lower LDL-C at 1 year

300 he body weight was <50 kg or the patient had coronary heart disease), with dose adjustment according